ArticleJournal of veterinary internal medicine2019
Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin.
Article in Journal of veterinary internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Impact of Doxorubicin on Cardiac Function in Dogs: Ejection Fraction Changes and Heart Failure Risk.Veterinary medicine and science · 2025Pooled it
- Comparative analysis of the cardiotoxicity induced by doxorubicin and epirubicin and exploratory investigations of clinical parameters indicating the cardiotoxicity in healthy dogs.The Journal of veterinary medical science · 2026Article
- Longitudinal echocardiographic systolic changes in dogs receiving doxorubicin-based chemotherapy.BMC veterinary research · 2026Article
- Feline leukemia virus-negative acute lymphoid B-cell aleukemic leukemia in a cat with prolonged survival.The Canadian veterinary journal = La revue veterinaire canadienne · 2026Article
- Retrospective Study Evaluating Outcomes Following Palliative Radiotherapy With or Without Chemotherapy for Dogs With Presumed Cardiac Hemangiosarcoma.Veterinary and comparative oncology · 2025Article
- PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer.BMC veterinary research · 2025Article
- Younger Age Is Associated with Favorable Outcomes in Adult Dogs with Hemangiosarcoma Receiving Adjuvant Doxorubicin Chemotherapy: Results from the PRO-DOX Study.Research square · 2025Article
- Advances in Targeted Autophagy Modulation Strategies to Treat Cancer and Associated Treatment-Induced Cardiotoxicity.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Evaluating the impact of doxorubicin preconditioning on the efficacy of inhaled recombinant human IL-15 immunotherapy in dogs with pulmonary metastasis.Veterinary oncology (London, England) · 2025Article
- Early detection of subclinical heart disease via nonlinear heart rate variability in a doxorubicin-induced cardiomyopathy experimental model in dogs.Frontiers in veterinary science · 2025Article
- Clinical Outcome of Multicentric Lymphoma Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (CHOP) in Small Breed Dogs.Animals : an open access journal from MDPI · 2024Article
- Effects of chemotherapy treatment with doxorubicin on right ventricular function in dogs.The Journal of veterinary medical science · 2024Article
- Hematological and blood biochemistry parameters as prognostic indicators of survival in canine multicentric lymphoma treated with COP and L-COP protocols.Veterinary world · 2024Article
- Comparison of echocardiographic measurements and cardiac biomarkers in healthy dogs eating nontraditional or traditional diets.Journal of veterinary internal medicine · 2023Article
- SonicatedCurrent issues in molecular biology · 2022Article
- Toxicity, outcome, and management of anthracycline overdoses in 16 dogs.Journal of veterinary internal medicine · 2022Article
- The Feline Cardiomyopathies: 1. General concepts.Journal of feline medicine and surgery · 2021Article
- The Utility of Intraventricular Pressure Gradient for Early Detection of Chemotherapy-Induced Subclinical Cardiac Dysfunction in Dogs.Animals : an open access journal from MDPI · 2021Article
- Phase I dose escalation study of 12b80 (hydroxybisphosphonate linked doxorubicin) in naturally occurring osteosarcoma.Oncotarget · 2020Article
- Review of canine dilated cardiomyopathy in the wake of diet-associated concerns.Journal of animal science · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDoxorubicin (DOX) can cause cumulative cardiotoxicity in dogs, but the incidence of clinical cardiotoxicity in dogs receiving DOX has not been determined. HYPOTHESIS/
objectivesTo determine if the duration of DOX infusion influences the incidence of cardiotoxicity, to characterize the incidence of clinical cardiotoxicity in dogs during or after DOX chemotherapy, and to identify any risk factors associated with cardiotoxicity. ANIMALS: Four-hundred ninety-four dogs that received at least 1 dose of DOX for the treatment of cancer.
methodsRetrospective study of dogs that received DOX from 2006 to 2015.
resultsOf 494 dogs, 20 (4.0%) developed clinical cardiotoxicity. The duration of DOX infusion was not significantly associated with clinical cardiotoxicity, whereas a higher cumulative dose of DOX, higher body weight, decreases in fractional shortening after 5 doses of DOX, and development of ventricular premature contractions were significantly associated with clinical cardiotoxicity. High-risk breeds for developing dilated cardiomyopathy had an incidence of 15.4%, whereas low-risk breeds had an incidence of 3.0%. CONCLUSIONS AND CLINICAL IMPORTANCE: Although the duration of DOX infusion did not influence the incidence of cardiotoxicity, premature contractions and decreases in fractional shortening should raise concern for the development of clinical cardiotoxicity. Overall, the incidence of clinical DOX-induced cardiotoxicity is low, but Boxers and other breeds at high risk for dilated cardiomyopathy may be at an increased risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.